Zhang Y - Search Results

1

Current advances in bacteria-based cancer immunotherapy.

Guo C, Liu J, Zhang Y. Guo C, et al. Among authors: zhang y. Eur J Immunol. 2024 Feb;54(2):e2350778. doi: 10.1002/eji.202350778. Epub 2023 Dec 17. Eur J Immunol. 2024. PMID: 38105295 Review.

2

Epigenetic inactivation of SPINT2 is associated with tumor suppressive function in esophageal squamous cell carcinoma.

Yue D, Fan Q, Chen X, Li F, Wang L, Huang L, Dong W, Chen X, Zhang Z, Liu J, Wang F, Wang M, Zhang B, Zhang Y. Yue D, et al. Among authors: zhang b, zhang z, zhang y. Exp Cell Res. 2014 Mar 10;322(1):149-58. doi: 10.1016/j.yexcr.2013.11.009. Epub 2013 Nov 21. Exp Cell Res. 2014. PMID: 24269829

3

Modification of chemokine receptor expression to enhance levels of trafficking receptors on autologous cytokine-induced killer cells derived from patients with colorectal cancer.

Wang D, Li J, Liu JY, Li F, Wang LP, Huang L, Li JY, Chen XF, Liu JB, Wu CC, Yuan WT, Wang GX, Song JM, Yue DL, Zhang Z, Ping Y, Wang RR, Zhang JY, Zhang Y. Wang D, et al. Among authors: zhang jy, zhang z, zhang y. Biomed Pharmacother. 2014 Jun;68(5):551-6. doi: 10.1016/j.biopha.2014.04.004. Epub 2014 Apr 28. Biomed Pharmacother. 2014. PMID: 24855035

4

Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer.

Li JY, Duan XF, Wang LP, Xu YJ, Huang L, Zhang TF, Liu JY, Li F, Zhang Z, Yue DL, Wang F, Zhang B, Zhang Y. Li JY, et al. Among authors: zhang b, zhang tf, zhang z, zhang y. J Immunol Res. 2014;2014:286170. doi: 10.1155/2014/286170. Epub 2014 Apr 28. J Immunol Res. 2014. PMID: 24868562 Free PMC article.

5

Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies.

Sun S, Hao H, Yang G, Zhang Y, Fu Y. Sun S, et al. Among authors: zhang y. J Immunol Res. 2018 Apr 17;2018:2386187. doi: 10.1155/2018/2386187. eCollection 2018. J Immunol Res. 2018. PMID: 29850622 Free PMC article. Review.

6

COVID-19: immunopathogenesis and Immunotherapeutics.

Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, Chen Y, Zhang Y. Yang L, et al. Among authors: zhang z, zhang y. Signal Transduct Target Ther. 2020 Jul 25;5(1):128. doi: 10.1038/s41392-020-00243-2. Signal Transduct Target Ther. 2020. PMID: 32712629 Free PMC article. Review.

7

PD-1 abrogates the prolonged persistence of CD8⁺ CAR-T cells with 4-1BB co-stimulation.

Li F, Zhang Z, Xuan Y, Zhang D, Liu J, Li A, Wang S, Li T, Shi X, Zhang Y. Li F, et al. Among authors: zhang d, zhang z, zhang y. Signal Transduct Target Ther. 2020 Aug 25;5(1):164. doi: 10.1038/s41392-020-00277-6. Signal Transduct Target Ther. 2020. PMID: 32843615 Free PMC article. No abstract available.

8

Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy.

Zhang Z, Chen X, Tian Y, Li F, Zhao X, Liu J, Yao C, Zhang Y. Zhang Z, et al. Among authors: zhang y. J Immunother Cancer. 2020 Oct;8(2):e001150. doi: 10.1136/jitc-2020-001150. J Immunother Cancer. 2020. PMID: 33023981 Free PMC article.

9

PMN-MDSCs-induced accumulation of CD8+CD39+ T cells predicts the efficacy of chemotherapy in esophageal squamous cell carcinoma.

Qin G, Liu J, Lian J, Zhang H, Lei Q, Yang H, Shao J, Chen X, Zhang B, Zhang Y. Qin G, et al. Among authors: zhang b, zhang h, zhang y. Clin Transl Med. 2020 Nov;10(7):e232. doi: 10.1002/ctm2.232. Clin Transl Med. 2020. PMID: 33252852 Free PMC article. No abstract available.

10

IL-33/ST2 as a potential target for tumor immunotherapy.

Jiang W, Lian J, Yue Y, Zhang Y. Jiang W, et al. Among authors: zhang y. Eur J Immunol. 2021 Aug;51(8):1943-1955. doi: 10.1002/eji.202149175. Epub 2021 Jun 23. Eur J Immunol. 2021. PMID: 34131922 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

241,113 results

Search Page